The COVID-19 Pandemic: Consideration for Brain Infection
The COVID-19 Pandemic: Consideration for Brain Infection
复制标题
COVID-19 大流行：考虑脑部感染。
DOI：
10.1016/j.neuroscience.2020.04.044
复制
发表时间：
2020-06-15
期刊：
影响因子：
3.3
通讯作者：
Jin, Wei-Lin
中科院分区：
文献类型：
--
作者：
Mao, Xiao-Yuan;Jin, Wei-Lin
于二零一九年十二月，位于中国武汉市的华南海鲜市场爆发新型冠状病毒病2019（COVID-19）。过去几个月，世界各地的COVID-19病例加速增加。截至2020年4月21日，共宣布2，397，217例确诊病例和162，956例死亡病例。COVID-19是由一种新病毒产生的，该病毒属于β-冠状病毒的第2组，包含严重急性呼吸系统综合征冠状病毒，即SARS-CoV-2。与此同时，COVID-19患者通常会出现呼吸系统并发症，如咳嗽、呼吸功能不全和发热。近年来，越来越多的证据表明，新型冠状病毒不仅攻击呼吸系统，还可能侵入中枢神经系统（CNS），出现神经系统症状。在回顾性分析中，记录了36.4%（78/214）的SARS-CoV-2感染患者具有神经学表现，包括急性脑血管疾病、意识障碍和感觉异常（Mao et al.，2020年）。严重感染的患者比死于轻度疾病的患者更容易出现神经系统症状。支持神经感染的证据也来自2020年3月4日在北京地坛医院由SARS-CoV-2引起的病毒性脑炎病例（Moriguchi等人，2020年）。研究人员首次报道，通过基因组测序，脑脊液对SARS-CoV-2 RNA检测呈阳性（Moriguchi et al.，2020年），表明该病毒的神经侵袭潜力。
In December 2019, an outbreak of novel Corona Virus Disease 2019 (COVID-19) emerged in the Huanan Seafood Market, which is located in Wuhan city, China. In the past few months, COVID-19 cases have accelerated all over the world. As of Apr 21st, 2020, a total of 2,397,217 confirmed cases and 162,956 deaths have been announced. Nowadays, it has been declared as a global public health threat by WHO due to a high rate of morbidity and mortality worldwide.COVID-19 is produced by a new virus which belongs to the Group 2 of beta-coronavirus that contains Severe Acute Respiratory Syndrome Coronavirus, namely, SARS-CoV-2. In parallel with this knowledge, COVID-19 patients commonly manifest respiratory complications, such as cough, respiratory insufficiency and fever. Recently, increasing evidence shows that the novel coronavirus not only attacks respiratory system, but also likely invades the central nervous system (CNS), developing neurological symptoms. In a retrospective analysis, it was documented that 36.4%(78/214) of SARS-CoV-2-infected patients possessed neurological manifestations including acute cerebrovascular diseases, disturbed consciousness and paresthesia (Mao et al., 2020). Severely infected patients are particularly more vulnerable to occurrence of neurological symptoms than patients who succumb to mild disease. The evidence supporting neuroinfection also arises from a case of viral encephalitis caused by SARS-CoV-2 in Beijing Ditan Hospital on Mar 4th, 2020 (Moriguchi et al., 2020). The researchers firstly reported that the cerebrospinal fluid tested positive for SARS-CoV-2 RNA by genome sequencing (Moriguchi et al., 2020), suggesting the neuroinvasive potential for the virus.